Michael R Schrimpf

USPTO Granted Patents = 37 (Patent Applications = 16)

CIPO Patents = 3 (Patent Applications = 16)

EPO Patents = 11 (Patent Applications = 20)

Average Co-Inventor Count = 6.0

ph-index = 7

Forward Citations = 164(Granted Patents)

Company Filing History:

Abbott Laboratories Corporation

where one patent can have more than one assignee

Years Active: 2004-2019

Loading Chart...

37 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10508113 - Inhibitors of tyrosine kinase 2 mediated signaling (2019-12-17),

2. 9983218 - Indole and indoline derivatives and methods of use thereof (2018-05-29),

3. 9625475 - Indole and indoline derivatives and methods of use thereof (2017-04-18),

4. 9382258 - Agents for treating pain and uses thereof (2016-07-05),

5. 9186407 - Pharmaceutical compositions and their methods of use (2015-11-17),

6. 9063126 - Indole and indoline derivatives and methods of use thereof (2015-06-23),

7. 9029361 - Agents for treating pain and uses thereof (2015-05-12),

8. 8987453 - Azaadamantane derivatives and methods of use (2015-03-24),

9. 8940762 - Methods for treating pain (2015-01-27),

10. 8846661 - Diazahomoadamantane derivatives and methods of use thereof (2014-09-30),

11. 8796470 - Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators (2014-08-05),

12. 8778959 - AZA-bridged ring-fused indoles and indolines (2014-07-15),

13. 8691865 - Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers (2014-04-08),

14. 8669255 - Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers (2014-03-11),

15. 8648074 - [object Object] (2014-02-11),

Title: Michael R. Schrimpf: Innovator in Pharmaceutical Chemistry

Introduction

Michael R. Schrimpf, based in Grayslake, IL, is a distinguished inventor with a successful portfolio of 37 patents. His work primarily focuses on pharmaceutical compounds, which have significant implications in medical research and treatment.

Latest Patents

Among his latest contributions to the field, Schrimpf has developed innovative compounds aimed at inhibiting tyrosine kinase 2 mediated signaling. These compounds, outlined in his patent, consist of specific formulas and pharmaceutically acceptable salts, showcasing their potential for therapeutic applications. Additionally, he has explored indole and indoline derivatives, detailing their formulas and methods of use. These derivatives are associated with compositions and approaches for treating various disease conditions, emphasizing the importance of his research in advancing pharmaceutical science.

Career Highlights

Throughout his career, Michael Schrimpf has worked with leading companies in the pharmaceutical industry, including AbbVie Inc. and Abbott Laboratories. His experience at these organizations has contributed to his development of novel compounds and pharmaceutical solutions that address critical health needs.

Collaborations

Schrimpf has collaborated with esteemed colleagues such as Kevin B. Sippy and William H. Bunnelle. These partnerships have fostered an environment of innovation, allowing for the exchange of ideas and expertise which enhances the development of effective pharmaceutical products.

Conclusion

Michael R. Schrimpf exemplifies the spirit of innovation within the pharmaceutical sector. With numerous patents to his name, his contributions have significantly advanced the field of medical chemistry, providing new avenues for research and treatment. His collaborations and career in prominent companies reflect his dedication to improving health outcomes through scientific discovery.

This text is generated by artificial intelligence and may not be accurate.